National Cancer Institute News
TCGA study of liver cancer reveals potential targets for therapy
Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist.
Study estimates number of U.S. women living with metastatic breast cancer
A new study shows that the number of women in the United States living with distant metastatic breast cancer (MBC), the most severe form of the disease, is growing. This is likely due to the aging of the U.S. population and improvements in treatment.
Annual Report to the Nation: Cancer death rates continue to decline
According to the latest Annual Report to the Nation on the Status of Cancer, 1975-2014, overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups. But more work remains for some cancers.
NCI launches study of African-American cancer survivors
The Detroit Research on Cancer Survivors (ROCS) study, which will include 5,560 cancer survivors, will look at the major factors affecting cancer progression, recurrence, mortality, and quality of life among African-American cancer survivors.
Study finds premature death rates diverge in the United States by race and ethnicity
Premature death rates declined among Hispanics, blacks, and Asian/Pacific Islanders due mainly to fewer deaths from cancer, heart disease, and HIV. Rising deaths from accidents, drug overdoses, suicide and liver disease increased rates among whites and American Indian/Alaska Natives.
TCGA study identifies genomic features of cervical cancer
Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in subclassification of the disease and may help target therapies that are most appropriate for each patient.
New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials
The National Cancer Institute (NCI) today launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials. The NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.
Who Should Get the HPV Vaccination and Why
Human papillomavirus (HPV) is the most common sexually transmitted infection in the US according to the Centers for Disease Control and Prevention (CDC).
Cancer Facts and Figures: Death Rate Down 25% Since 1991
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
10 Powerful Survivor Stories From 2016
Our featured survivors share words of inspiration, wisdom, hope, and support in these stories about how their lives have been changed by cancer.
- Next Page